Drug intelligence / Profile preview

anti-CD20-IFNα

Development stage: Unknown
Lead developer: Assertio
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

anti-CD20-IFNα is a Phase 1 fusion molecule developed for the treatment of non-Hodgkin’s lymphoma. It is a fusion protein that combines an anti-CD20 antibody component with Interferon alpha (IFNα). The technology, known as Fusion Interferon Technology (FIT), originated from UCLA and was acquired by Spectrum Pharmaceuticals from ImmunGene, Inc. This drug is designed to expand Spectrum's pipeline with an innovative immuno-oncology platform, leveraging the targeted delivery of IFNα to CD20-expressing cells.

Targets

CD20 (B-lymphocyte antigen CD20)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on anti-CD20-IFNα.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD20-IFNα.

Explore the full profile